AstraZeneca said ​on Thursday ‌its asthma drug, ​Tezspire, ​developed with Amgen , ⁠met ​its main ​and secondary goals in ​a ​late-stage trial for ‌treating ⁠eosinophilic esophagitis, a chronic ​inflammatory ​disorder ⁠of the ​esophagus.